XML 39 R27.htm IDEA: XBRL DOCUMENT v3.20.2
Research, Collaboration and License Agreements - Additional Information (Details)
1 Months Ended 3 Months Ended 9 Months Ended
Oct. 31, 2020
USD ($)
Aug. 31, 2020
USD ($)
Apr. 30, 2020
USD ($)
Product
Dec. 31, 2019
USD ($)
shares
Sep. 30, 2020
USD ($)
shares
Sep. 30, 2020
USD ($)
shares
Mar. 31, 2020
shares
Feb. 21, 2020
USD ($)
Nov. 30, 2019
shares
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Common stock, shares issued | shares       10,894,999 37,761,435 37,761,435      
Research and development         $ 11,057,000 $ 19,633,000      
UT Southwestern Agreement                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Preclinical activities period under sponsored research agreements     2 years            
Minimum licensed product to develop obtain regulatory approval for and commercialize | Product     1            
Common stock, shares issued | shares             0   2,179,000
Percentage of fully diluted common stock shares outstanding                 20.00%
Percentage of entitled to receive additional shares on fully diluted basis                 10.00%
Queen's Agreement                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Research grant of committed fund amount       $ 3,800,000          
Percentage of interest rate       6.00%          
Research grant outstanding fund amount         $ 0 0      
Queen's Agreement | Research and Development Expense                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Cash payment to acquire license agreement     $ 3,000,000            
Queen's Agreement | Maximum                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
License agreement regulatory milestones payment               $ 10,000,000  
License agreement commercial milestones payment               $ 10,000,000  
Abeona CLN1 Agreements                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
License fee payment   $ 3,000,000              
Research and development           $ 7,000,000      
Abeona CLN1 Agreements | Subsequent Event                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Purchase of clinical materials and reimbursement incurred development costs $ 4,000,000                
Abeona CLN1 Agreements | Maximum                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
License and inventory purchase agreement regulatory related milestones payment   26,000,000              
License and inventory purchase agreement sales related milestones payment   $ 30,000,000